This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

JOHN ROGERS, B.Sc., M.B., Ch.B.; OWEN A. FINN, M.D.

AMA Arch Derm. 1956;74(4):387-388.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In a previous communication¹ we pointed out that chloroquine (7-chloro-4-[4-diethylamino-1-methylbutylamino ] quinoline ) diphosphate could replace quinacrine (3-chloro-7-methoxy-9-[1 methyl-4-diethylaminobutylamino] acridine dihydrochloride) in the treatment of chronic discoid lupus erythematosus and light eruptions but stated that there was no evidence to suggest that the therapeutic effect of chloroquine would be any more permanent than that of quinacrine. Although numerous reports have appeared on the use of synthetic antimalarial drugs, there are few details available on the question of relapse after cessation of therapy. We have therefore reviewed our results of treatment with quinacrine and chloroquine with special reference to recurrence of lesions after therapy has been discontinued.

Dosage Schedule

Quinacrine.—The majority of patients received 0.1 gm. three times daily for one month, then 0.1 gm. twice daily for the next month, and finally 0.1 gm. daily for the remainder of . . . [Full Text PDF of this Article]

Author Affiliations
Dundee, Scotland

From the Department of Dermatology, University of St. Andrews.

Footnotes
Submitted for publication Dec. 31, 1955.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?